Compare Old Dominion Freight Line Inc (ODFL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Old Dominion Freight Line Inc trades at $183.23 (market cap $36.42B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.1× Old Dominion Freight Line Inc's market cap, and Old Dominion Freight Line Inc pays the higher dividend (0.66%). Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ODFL | REGN | |
|---|---|---|
Market Cap | $36.42B | $76.40B |
Volume | 1,668,932 | 626,381 |
Sector | Industrials | Health |
52-Week High | $248.73 | $852.03 |
52-Week Low | $126.29 | $557.73 |
Typical Hold Time | 76 Days | 107 Days |
Enterprise Value | $36.15B | $71.12B |
Dividend Yield | 0.66% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $181.65, up 2.04% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though revenue declined to $5.5B in 2025. Recent news highlights a 4.9% general rate increase effective October 5, 2026, aimed at offsetting operating costs while supporting service investments.
ODFL presents a mixed outlook with Wall Street's $230.93 consensus target suggesting 27% upside, yet technical indicators remain bearish. The stock's premium valuation (P/E 33.77) requires sustained earnings growth, while competitive pressures and freight demand volatility pose risks. Institutional buying and oversold technical conditions may support near-term recovery potential.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
